Intestinal PD-L1 Expression via Chitosan Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of PD-L1's role in T cell activation is limited, particularly in immune protective settings, which hinders the therapeutic potential of PD-L1 in inflammatory disorders such as inflammatory bowel disease and graft-versus-host disease.
Innovation Solution
Localized intestinal expression of PD-L1 polypeptides, including soluble forms, using expression vectors encapsulated in chitosan or chitosan derivative nanoparticles to administer PD-L1 nucleic acids, facilitating targeted treatment of inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If soluble PD-L1 is administered to enhance T cell response, then T cell activation is improved, but graft-versus-host disease is exacerbated
Solution Approach 1:
The patent applies local quality by administering PD-L1 specifically to the intestinal tract rather than systemically. This localized administration allows PD-L1 to act on T cells in the intestinal microenvironment where it can modulate immune responses in inflammatory bowel disease without causing the harmful effects of systemic T cell enhancement that lead to graft-versus-host disease
Solution Approach 2:
The patent uses chitosan nanoparticles as an intermediary delivery system that targets PD-L1 to the intestinal tract. This intermediary enables controlled local delivery of PD-L1, ensuring it reaches the intended site of action in the intestine while preventing systemic distribution that would cause harmful effects
2Object-affected harmful factors
If PD-L1 is administered to treat inflammatory bowel disease, then disease severity is reduced, but localized delivery to the intestinal tract is required to avoid systemic effects
Solution Approach 1:
Chitosan nanoparticles serve as an intermediary delivery vehicle that simplifies the overall system by providing targeted intestinal delivery through a single administration route. This intermediary handles the complexity of localization, allowing simple oral or rectal administration to achieve targeted intestinal delivery without requiring complex localized delivery infrastructure
Solution Approach 2:
The chitosan nanoparticles exhibit self-targeting properties to the intestinal tract through their material characteristics and interaction with the gastrointestinal environment. This self-service capability reduces the need for complex external targeting mechanisms, as the delivery system automatically localizes to the intended site based on its inherent properties
Data Source
AI summary
Provided herein are methods and compositions for the amelioration of inflammatory disorders comprising the intestinal expression of programmed death ligand 1.